Open AccessThe impact of charlson comorbidity index on mortality from SARS‐CoV‐2 virus infection and A novel COVID‐19 mortality index: CoLACD
Author(s) -
Varol Yelda,
Hakoglu Burcin,
Kadri Cirak Ali,
Polat Gulru,
Komurcuoglu Berna,
Akkol Berrin,
Atasoy Cagri,
Bayramic Eda,
Balci Gunseli,
Ataman Sena,
Ermin Sinem,
Yalniz Enver
Publication year - 2021
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.13858
Subject(s) - medicine , comorbidity , youden's j statistic , pneumonia , univariate analysis , odds ratio , receiver operating characteristic , covid-19 , multivariate analysis , pneumonia severity index , risk of mortality , logistic regression , area under the curve , severity of illness , univariate , multivariate statistics , community acquired pneumonia , disease , infectious disease (medical specialty) , statistics , mathematics
Objective The aim of this study is to find out the potential risk factors including charlson comorbidity index (CCI) score associated with death in COVID‐19 patients hospitalised because of pneumonia and try to find a novel COVID‐19 mortality score for daily use. Methods All patients diagnosed as confirmed or probable COVID‐19 pneumonia whom hospitalised in our Chest Diseases Education and Research Hospital between March 11, 2020 and May 15, 2020 were enrolled. The optimal cut‐off values, sensitivity and specificity values and odds ratios to be used in mortality prediction of the novel scoring system created from these parameters were calculated by ROC analysis according to the area under the curve and Youden index. Results Over 383 patients (n: 33 deceased, n: 350 survivors) univariate and multivariate regression analysis showed that CCI and lymphocyte ratio were prognostic factors for COVID‐19‐related mortality. Using this analysis, a novel scoring model CoLACD ( Co VID‐19 L ymphocyte ratio, A ge, C CI score, D yspnoea) was established. The cut‐off value of this scoring system, which determines the mortality risk in patients, was 2.5 points with 82% sensitivity and 73% specificity (AUC = 0.802, 95% CI 0.777‐0.886, P < .001). The risk of mortality was 11.8 times higher in patients with a CoLACD mortality score higher than 2.5 points than patients with a score lower than 2.5 (OR = 11.8 95% CI 4.7‐29.3 P < .001). Conclusion This study showed that by using the CoLACD mortality score, clinicians may achieve a prediction of mortality in COVID‐19 patients hospitalised for pneumonia.